No Link for Cardiovascular Meds Use, Cognitive Impairment

This article originally appeared here.
Share this content:
No Link for Cardiovascular Meds Use, Cognitive Impairment
No Link for Cardiovascular Meds Use, Cognitive Impairment

THURSDAY, Aug. 31, 2017 (HealthDay News) -- For older adults, there is no association between cardiovascular medication use and cognitive impairment, according to a study published online Aug. 24 in Cardiovascular Therapeutics.

Daniela Rohde, from the Royal College of Surgeons in Dublin, and colleagues examined the correlation between cardiovascular medication use and cognitive impairment in an analysis of 1,903 participants (age 50 years and older) from wave 1 of the Irish Longitudinal Study on Ageing. The authors calculated cardiovascular medication use by using the proportion of days covered for antihypertensive, antithrombotic, and lipid-modifying medications.

The researchers found that there was no evidence of an independent correlation between impaired cognitive function and antihypertensive use (good adherence odds ratio, 1.16 [95 percent confidence interval, 0.88 to 1.52]; poor adherence odds ratio, 1.39 [95 percent confidence interval, 0.95 to 2.04]), antithrombotic use (good adherence odds ratio, 1.26 [95 percent confidence interval, 0.93 to 1.7]; poor adherence odds ratio, 1.13 [95 percent confidence interval, 0.8 to 1.59]), or lipid-modifying agent use (good adherence odds ratio, 0.95 [95 percent confidence interval, 0.71 to 1.25]; poor adherence odds ratio, 0.88 [95 percent confidence interval, 0.64 to 1.22]) after controlling for demographic and health variables.

"We found no evidence of an association between cardiovascular medication use and cognitive function," the authors write. "Future studies should investigate the prospective associations between cognition and use of cardiovascular medications using longitudinal data."

One author disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »